Cencora Patient Support Services (Lash Group)

Overview

Cencora Patient Support Services (Lash Group) is the legacy hub-services brand for Cencora’s U.S. patient-services and free-goods pharmacy operations, including AmerisourceBergen Lash Group and TheraCom search intent. As of April 27, 2026, CareMetx operates the U.S.-based patient-services and free-goods pharmacy operations acquired from Cencora; buyers searching Lash Group, Cencora Patient Support Services, or TheraCom should evaluate CareMetx as the current operator for those acquired services.

This page is not the current vendor for new manufacturer RFPs. Pre-April-2026 history: Cencora’s Patient Support Services division, historically branded as Lash Group, was one of the founding hub-services providers in the United States, operating continuously since 1986 with 30+ years of experience and 18M+ patients served. The Cencora relationship mattered because Lash integrated hub services with Cencora’s distribution network before the divestiture; that integration moves with the operations to CareMetx, while Cencora retains the distribution role.

For a biopharma launch team evaluating today, route to the CareMetx profile for the operating hub book. Use this page to confirm historical scope, lineage, and the acquisition timeline.

Hub Capability Model

The historical capabilities below transferred to CareMetx on April 27, 2026. Buyers should evaluate the current state on the CareMetx profile; this table is preserved for diligence on legacy Lash Group / TheraCom programs and contract lineage.

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Lash Group / TheraCom is evaluated as a historical hub-services operating model now transferred to CareMetx.

Capability	Buyer should compare	Cencora Patient Support Services (Lash Group) readout (historical)
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Patient intake, eligibility screening, and program onboarding ran inside the Lash Group operating model; now under CareMetx.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Eva AI digital assistant automated payer benefit-verification calls; transferred with the operations.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	PA, appeals, and field reimbursement teams ran under Lash Group; CareMetx now owns the operating model.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Copay-card management, PAP enrollment, foundation and charity grants, and 340B coordination were in scope; transferred to CareMetx.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Clinical-nurse support, injection training, and patient education sat inside Lash Group; CareMetx now operates the patient-facing layer.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	TheraCom 50-state-licensed specialty pharmacy for free-goods dispensing transferred to CareMetx; Cencora retains commercial distribution.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Manufacturer reporting, KPI dashboards, and SLA governance now sit on the CareMetx platform; legacy contracts and feed structures need transition review.

Buyer Fit

• Current operator (April 2026): CareMetx now operates the U.S. patient-services and free-goods pharmacy operations historically delivered under the Lash Group brand. New RFPs and active program evaluations route to CareMetx.
• Use this profile for: Diligence on legacy Lash Group / TheraCom / AmerisourceBergen Lash Group programs, contract lineage, prior commitments, or buyer search-intent routing from the old brand.
• Therapy and product fit (historical): Oncology, Cell & Gene Therapy, Rare Disease, Immunology/Autoimmune, and Ophthalmology launches; drug-type fit historically spanned Specialty, Biologics, Cell Therapy, Gene Therapy, and Biosimilars.
• Commercial fit (historical): Custom/RFP pricing with service levels, data feeds, launch timing, and governance defined in the statement of work.
• Validate with CareMetx, not here: Staffing model, launch-surge plan, data feeds, and division of labor with specialty pharmacies all transfer with the operations.

Differentiators (historical)

These are the legacy attributes that travel with the operations to CareMetx as of April 2026. Diligence on the post-transfer state belongs in the CareMetx profile.

• 30+ years and 18M+ patients served across 100+ support programs: One of the oldest and largest hub-services providers in the U.S., now folded into the CareMetx patient-services platform.
• TheraCom 50-state-licensed specialty pharmacy for free-goods dispensing: Non-commercial dispensing footprint that transfers to CareMetx alongside the hub book.
• Eva AI digital assistant for automated payer benefit verification calls: AI-driven electronic BV that ran inside the Lash Group operating model pre-divestiture.
• Clinical nurse support, injection training, education, and field reimbursement teams: High-touch clinical infrastructure built up across 30+ years of hub operations.
• Distribution integration with Cencora (pre-divestiture): Hub services historically sat next to Cencora’s distribution network; post-April-2026, the distribution role stays with Cencora while the hub operations move to CareMetx.

RFP Questions

These belong in a CareMetx RFP now, not a Cencora Lash Group RFP. Cross-link buyers searching the legacy name to the current operator.

• Which legacy Lash Group / TheraCom programs, contracts, and SLAs transfer cleanly to CareMetx, and which require renegotiation?
• What median time-to-therapy, PA turnaround, and first-fill conversion metrics are reported on the CareMetx platform post-transfer?
• How are benefit verification, PAP, copay, and adherence data reconciled into manufacturer dashboards under the new operator?
• What launch-surge staffing, training, and bilingual coverage commitments are available from CareMetx in the first 90 days of a transferred program?

Recent Activity

• Apr 2026 - U.S. patient-services and free-goods pharmacy operations (legacy Lash Group + TheraCom) acquired by CareMetx; Cencora simultaneously contracted CareMetx as its preferred U.S. patient-services partner post-divestiture.
• Nov 2025 - Legacy U.S. hub services classified as non-core and moved to “Other” segment; strategic alternatives explored (resolved Apr 2026 via the CareMetx divestiture).
• Oct 2024 - Robert P. (Bob) Mauch (from COO) appointed President and CEO of Cencora parent, succeeding retiring Steven H. Collis (transitioned to Executive Chair).